NCT03675256 - The KEN SHE Study on HPV-vaccine Efficacy | Biotech Hunter

Enrollment

2,275

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

February 15, 2024

Study Completion Date

February 15, 2024

Conditions

Papillomavirus Infections

Interventions

BIOLOGICAL

immediate Gardasil 9, delayed MenVeo vaccine

Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine

BIOLOGICAL

immediate MenVeo vaccine, delayed Gardasil 9

Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9

BIOLOGICAL

immediate Cervarix, delayed MenVeo vaccine

Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine

Trial Locations (3)

Partners in Health, Research and Development, Thika

Kargeno Research and Policy Hub, Kisumu

Center for Clinical Research, Nairobi